Genitourinary
Shuang (George) Zhao, MD
The Zhao Lab focuses on developing novel clinical biomarkers that predict response and resistance to specific therapies across cancers. These biomarkers can be used to better select which patients derive a benefit from treatment, which patients do not and can be spared potential toxicity, as well as monitor for emergence of resistance. It seeks to use advanced computational approaches and liquid biopsy technologies to better personalize the care of cancer patients.
John Floberg, MD, PhD
Clinically, Dr. Floberg focuses on the treatment of genitourinary cancers. As a radiation oncologist, he collaborates with urologists, medical oncologists, radiologists, pathologists and other specialists to provide patients with the best care possible.
Pippa Cosper, MD, PhD
Dr. Cosper’s main interest is in Human Papilloma Virus (HPV) induced cancers, such as cervical and head and neck cancer. Specifically, she is interested in how the virus induces different types of chromosomal instability (CIN) and how this affects radiation sensitivity, which may offer some insight into radiation sensitivity or resistance within HPV+ cancers.
Gregory Cooley, MD
Dr. Cooley is a clinical associate professor in the Department of Human Oncology (DHO). The DHO is one of the few centers in the region offering both low-dose-rate and high-dose-rate prostate brachytherapy. Two decades ago, prostate brachytherapy showed superior PSA control rates. With further advances in dosing, fractionation and MRI-based planning, results are even better.